San Antonio Breast Cancer Conference Update
By: Dr. Tiffany Svahn
At the San Antonio Breast Cancer Symposium today, results of the international ATLAS trial were presented. This trial included nearly 7000 women with hormone-sensitive early stage breast cancer. The presenter, Dr. C. Davies from the United Kingdom, discussed the results of 5 years of adjuvant tamoxifen versus 10 years. Women who took tamoxifen for 10 years rather than 5 had a nearly 3% reduction in the risk of death. While modest, the benefit appears to be real and meaningful. This data may be most important in premenopausal women, as postmenopausal women tend to switch to aromatase inhibitors after 5 years of tamoxifen. This data may lead to a significant change in how we treat young women with early stage breast cancer.